acute lung injury
Conditions
Interventions
Experimental group:Conventional treatment+Iv sivelestat sodium
Control group:Conventional treatment
Sponsors
Fujian Medical University Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with cardiovascular surgery in the age range of 18 to 75 years old, who simultaneously meet the following two conditions: 1) Meet the criteria for acute lung injury, characterized by: ? Hypoxemia: PaO2/FiO2 (arterial oxygen partial pressure/fraction of inspired oxygen) = 300; ? Chest X-ray showing bilateral infiltrates; ? If pulmonary artery wedge pressure can be measured, pulmonary artery wedge pressure = 18 mmHg; if unable to measure pulmonary artery wedge pressure, no clinical evidence of elevated left atrial pressure. 2) Meet the diagnostic criteria for systemic inflammatory response syndrome (SIRS), and have two or more of the following: ? Fever (body temperature > 38.3?) or hypothermia (body temperature 90 beats/min; ? Tachypnea, respiratory rate > 20 breaths/min; ? Leukocytosis (white blood cell count > 12×109/L) or leukopenia (white blood cell count 10% band forms (immature white blood cells).
Exclusion criteria
Exclusion criteria: 1. Congestive heart failure with pulmonary artery wedge pressure =18 mmHg or clinical evidence of elevated left atrial pressure. 2. Use of glucocorticoids in the 4 weeks prior to hospitalization. 3. History of previous chemotherapy. 4. History of liver disease or significant abnormalities in liver function at the time of enrollment (aspartate aminotransferase, alanine aminotransferase levels more than twice the normal value). 5. History of severe chronic respiratory diseases (including but not limited to chronic obstructive pulmonary disease, interstitial lung disease, etc.). 6. Recent diagnosis of leukopenia or thrombocytopenia within the past year. 7. Acquired immune deficiency syndrome (AIDS) comorbidity. 8. Concurrent renal failure requiring hemodialysis or peritoneal dialysis. 9. Known allergy to the components of intravenous levosimendan. 10. Participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory factor;Expression of miR-503 and DUSP1 genes;Mechanical ventilation time;Oxygenation index; | — |
Countries
China
Contacts
Public ContactChen Sheng
Fujian Medical University Union Hospital
Outcome results
None listed